Sanofi to acquire Synthorx to bolster its immuno-oncology pipeline for $2.5 Billion
Sanofi and Synthorx, a clinical-stage biotechnology company focused on prolonging and improving the lives of people suffering from cancer and autoimmune disorders, entered into a…
Read More...
Read More...
